Strategic BACE1 Inhibition in Alzheimer’s Disease: Mechan...

2025-10-17

This thought-leadership article explores the evolving paradigm of beta-secretase (BACE1) inhibition in Alzheimer's disease research. By dissecting the mechanistic rationale, recent synaptic safety data, and strategic translational considerations, we highlight how Lanabecestat (AZD3293) empowers researchers to modulate the amyloidogenic pathway with unprecedented precision and confidence. Anchored by pivotal evidence and enriched by expert guidance, this piece serves as both a scientific deep-dive and a strategic roadmap for translational researchers.